The importance of targeting more pathways at the same time is highlighted by phase I-II clinical trials evaluating the clinical activity of JAK2 and/or PI3K inhibitors in relapsed refractory patients with HL (8, 38). The gene discussed is JAK2; the disease is Hodgkins lymphoma.